{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:32Z","timestamp":1791348572955,"version":"4.3.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000156","name":"Fonds de recherche du Qu\u00e9bec Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","onlinecjc.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.cjca.2024.02.027","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T17:23:35Z","timestamp":1709745815000},"page":"1718-1728","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinical Outcomes of Renin-Angiotensin-Aldosterone Blockade in Patients With Advanced Chronic Kidney Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7573-4138","authenticated-orcid":false,"given":"Nicolas","family":"Vendeville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7518-185X","authenticated-orcid":false,"given":"Marc-Antoine","family":"Lepage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carolina","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Mavrakanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2024.02.027_bib1","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib2","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.02.027_bib3","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.cjca.2024.02.027_bib4","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl (2011)"},{"key":"10.1016\/j.cjca.2024.02.027_bib5","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2024.02.027_bib6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/j.ajkd.2018.06.010","article-title":"Use of renin-angiotensin system blockade in advanced CKD: an NKF-KDOQI controversies report","volume":"72","author":"Weir","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2024.02.027_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.824095","article-title":"RAAS inhibitor prescription and hyperkalemia event in patients with chronic kidney disease: a single-center retrospective study","volume":"9","author":"Riccio","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"11 Suppl","key":"10.1016\/j.cjca.2024.02.027_bib8","first-page":"S212","article-title":"Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors","volume":"21","author":"Epstein","year":"2015","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.cjca.2024.02.027_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib10","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1681\/ASN.2020050682","article-title":"Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: a nationwide study","volume":"32","author":"Fu","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2024.02.027_bib11","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2215\/CJN.0000000000000127","article-title":"Time to abandon renalism: patients with kidney diseases deserve more","volume":"18","author":"Gaut","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2024.02.027_bib13","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2024.02.027_bib14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C\u2013based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib15","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2024.02.027_bib16","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2024.02.027_bib17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7650","key":"10.1016\/j.cjca.2024.02.027_bib18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"6958","key":"10.1016\/j.cjca.2024.02.027_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1136\/bmj.309.6958.833","article-title":"Randomised controlled trial of enalapril and beta blockers in nondiabetic chronic renal failure","volume":"309","author":"Hannedouche","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2024.02.027_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0272-6386(96)90158-4","article-title":"Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial","volume":"27","author":"Ihle","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2024.02.027_bib22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/ajh\/5.7.423","article-title":"Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial","volume":"5","author":"Kamper","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2024.02.027_bib23","doi-asserted-by":"crossref","first-page":"c139","DOI":"10.1159\/000086714","article-title":"A\u00a0prospective open-label randomised trial of quinapril and\/or amlodipine in progressive nondiabetic renal failure","volume":"101","author":"MacGregor","year":"2005","journal-title":"Nephron Clin Pract"},{"issue":"9176","key":"10.1016\/j.cjca.2024.02.027_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2024.02.027_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10157-008-0040-y","article-title":"Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease","volume":"12","author":"Tamura","year":"2008","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.cjca.2024.02.027_bib26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/ki.1992.309","article-title":"Long-term comparison between captopril and nifedipine in the progression of renal insufficiency","volume":"42","author":"Zucchelli","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2024.02.027_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.xkme.2019.12.007","article-title":"ACE inhibitor\/angiotensin receptor blocker use patterns in advanced CKD and risk of kidney failure and death","volume":"2","author":"Arora","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib29","doi-asserted-by":"crossref","first-page":"c73","DOI":"10.1159\/000342392","article-title":"Proteinuria as a risk marker for the progression of chronic kidney disease in patients on predialysis care and the role of angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker treatment","volume":"121","author":"de Goeij","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.cjca.2024.02.027_bib30","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/eurheartj\/ehv268","article-title":"Association between renin-angiotensin system antagonist use and mortality in heart failure with severe renal insufficiency: a prospective propensity score\u2013matched cohort study","volume":"36","author":"Edner","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2024.02.027_bib31","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.jacc.2016.01.050","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction","volume":"67","author":"Evans","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2024.02.027_bib32","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/j.ajkd.2020.10.006","article-title":"Comparative effectiveness of renin-angiotensin system inhibitors and calcium channel blockers in individuals with advanced CKD: a nationwide observational cohort study","volume":"77","author":"Fu","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2024.02.027_bib33","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2024.02.027_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1253\/circj.CJ-19-0782","article-title":"Effects of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in heart failure with chronic kidney disease\u2014propensity score matching analysis","volume":"84","author":"Kim","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.cjca.2024.02.027_bib35","article-title":"The impact of renin-angiotensin system blockade on renal outcomes and mortality in pre-dialysis patients with advanced chronic kidney disease","volume":"12","author":"Oh","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2024.02.027_bib36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1532-5415.1999.tb02993.x","article-title":"Angiotensin-converting enzyme inhibitor use in older patients with heart failure and renal dysfunction","volume":"47","author":"Philbin","year":"1999","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.cjca.2024.02.027_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5414\/CNP73139","article-title":"Renoprotective effects of telmisartan in patients with advanced chronic kidney disease","volume":"73","author":"Tokunaga","year":"2010","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.cjca.2024.02.027_bib38","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.jamda.2021.10.019","article-title":"Effectiveness and tolerance of renin-angiotensin system inhibitors with aging in chronic kidney disease","volume":"23","author":"Villain","year":"2022","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.cjca.2024.02.027_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ahj.2008.01.031","article-title":"Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis","volume":"155","author":"Balamuthusamy","year":"2008","journal-title":"Am Heart J"},{"key":"10.1016\/j.cjca.2024.02.027_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.662544","article-title":"Systematic review and meta-analysis of renin-angiotensin-aldosterone system blocker effects on the development of cardiovascular disease in patients with chronic kidney disease","volume":"12","author":"Yanai","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cjca.2024.02.027_bib41","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2024.02.027_bib42","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2024.02.027_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.kint.2017.08.038","article-title":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","volume":"93","author":"Georgianos","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2024.02.027_bib44","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/CIRCULATIONAHA.121.057736","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials","volume":"145","author":"Neuen","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2024.02.027_bib45","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24001922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X24001922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:27:25Z","timestamp":1725632845000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X24001922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0828282X24001922"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2024.02.027","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Renin-Angiotensin-Aldosterone Blockade in Patients With Advanced Chronic Kidney Disease: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2024.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the Canadian Cardiovascular Society.","name":"copyright","label":"Copyright"}]}}